🧫
Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression.
active
experiment
Created:
By: experiment_extractor
Quality:
50%
✓ SciDEX
ID: experiment-exp-27fad2412bd3
🧫 Experiment Protocol
Clinicalproposed
SUMMARY
Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression.
METHODOLOGY NOTES
Fluid biomarker detection of phosphorylated tau (pT217Tau)
species: homo_sapiens
▸Metadatasource: {'pmid': '40767321', 'type': 'paper', 'e
| source | {'pmid': '40767321', 'type': 'paper', 'extracted_by': 'llm_extraction_v1'} |
| tissue | None |
| species | homo_sapiens |
| summary | Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression. |
| sample_size | None |
| model_system | human |
| _schema_version | 1 |
| experiment_type | clinical |
| methodology_notes | Fluid biomarker detection of phosphorylated tau (pT217Tau) |
| replication_status | replicated |
| extraction_metadata | {'needs_review': False, 'extraction_date': '2026-04-28T06:17:19.878377+00:00', 'extraction_notes': '', 'extraction_confidence': 0.5} |
| statistical_evidence | None |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.